Biotechnology News and Research

RSS

Research examines differences between male and female brain that contributes to violent behavior

Human behaviors such as violence depend on interactions in the brain between genetic and environmental factors. An individual may be more vulnerable to developing violent behaviors if they have predisposing factors and are then exposed to stress, abuse, or other triggers, especially early in life.

6 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

New super-resolution microscopy method could spot dozens of distinct types of biomolecules

A new microscopy method could enable scientists to generate snapshots of dozens of different biomolecules at once in a single human cell, a team from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported Sunday in Nature Methods.

4 Feb 2014

Protein study opens new avenue for cancer researchers

One of the hopes for victory against cancer hinges on naturally-occurring proteins whose job is to make their host cell die. Since their natural role is to stop unhealthy cell proliferation, the idea is that one or more of these proteins could be harnessed to stop the growth of tumors.

3 Feb 2014

Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

In recognition of his seminal work on adenoviral vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic, Ronald G. Crystal, MD (Weill Cornell Medical College, Cornell University, New York City), has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

31 Jan 2014

Keystone Symposia to convene conference focusing on the science of malaria eradication

Keystone Symposia, in collaboration with MESA (Malaria Eradication Scientific Alliance), is convening its first conference in Mexico – on "The Science of Malaria Eradication" at the Fiesta Americana Hotel in Merida, Yucatan. The four-day conference begins Sunday evening, February 2, 2014 and is part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation, which has also funded travel awards for investigators from malaria-endemic countries to attend. The conference will gather experts from 37 countries.

31 Jan 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

New insight into how gut bacteria digest fibre

New insight into how gut bacteria digest fibre could lead to advances in areas as diverse as health and environmentally-friendly biofuels.

31 Jan 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

30 Jan 2014

University of Liverpool receives funding to continue reducing impact of adverse reactions to medicinal drugs

The Medical Research Council (MRC) Centre for Drug Safety Science at the University of Liverpool has received three million pounds of new funding from MRC to allow it to continue reducing the impact of adverse reactions to medicinal drugs.

30 Jan 2014

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

The Cystic Fibrosis Center at Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital has been selected by the Cystic Fibrosis Foundation (CFF) for the foundation's prestigious Quality Care Award for 2012-2013.

30 Jan 2014

Researchers design semi-synthetic proteins to analyse body's vital signal processes

Proteins play a fundamental role in almost all biological processes. They consist of chains constructed of up to 20 different amino acids, and their composition, structure and function are controlled by the genetic code.

29 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014.

28 Jan 2014

Study to evaluate connections between brain networks and religious thought

Building on previous evidence showing that religious belief involves cognitive activity that can be mapped to specific brain regions, a new study has found that causal, directional connections between these brain networks can be linked to differences in religious thought.

28 Jan 2014

Biotechnology News and Research

Research examines differences between male and female brain that contributes to violent behavior

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

New super-resolution microscopy method could spot dozens of distinct types of biomolecules

Protein study opens new avenue for cancer researchers

Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

Keystone Symposia to convene conference focusing on the science of malaria eradication

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

New insight into how gut bacteria digest fibre

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

University of Liverpool receives funding to continue reducing impact of adverse reactions to medicinal drugs

Cystic Fibrosis Center receives Quality Care Award for commitment to improve quality of care in CF patients

Researchers design semi-synthetic proteins to analyse body's vital signal processes

CU receives cooperative agreement to develop technological system to determine effects chemical agents

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Study to evaluate connections between brain networks and religious thought

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News